Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease

被引：25

作者：

Casademont, J

Miró, O

Rodriguez-Santiago, B

Viedma, P

Blesa, R

Cardellach, F

机构：

[1] Univ Barcelona, Fac Med, IDIBAPS, Hosp Clin,Internal Med Dept,Muscle Res Grp, Barcelona 08036, Catalonia, Spain

[2] Univ Barcelona, ICMSN, IDIBAPS, Hosp Clin,Memory Alzheimer Unit, Barcelona 08036, Catalonia, Spain

[3] IRO, Med & Mol Genet Ctr, Barcelona, Spain

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2003年 / 206卷 / 01期

关键词：

mitochondria; electron transport chain; respiratory chain; rivastigmine; neurodegenerative disorders; dementia;

D O I：

10.1016/S0022-510X(02)00319-2

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Electron transport chain (ETC) dysfunction has been claimed to contribute to the expression of neurodegenerative disorders. We have investigated the effects of the treatment with rivastigmine, a commonly used cholinesterase inhibitor, on lymphocyte mitochondria of patients with Alzheimer's disease (AD). Increased enzymatic activities of diverse complexes and oxidative capacity of the ETC were found. Enhanced mitochondrial ETC function may contribute to the beneficial effects of rivastigmine on clinical manifestations of AD. (C) 2002 Elsevier Science B.V. All rights reserved.

引用

页码：23 / 26

页数：4

共 50 条

[1] Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease
Gobburu, JVS
Tammara, V
Lesko, L
Jhee, SS
Sramek, JJ
Cutler, NR
Yuan, RH
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (10): : 1082 - 1090
[2] Switching cholinesterase inhibitor therapy in Alzheimer's disease - donepezil to rivastigmine, is it worth it?
Bullock, R
Connolly, C
[J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 17 (03) : 288 - 289
[3] Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease
Jann, MW
[J]. PHARMACOTHERAPY, 2000, 20 (01): : 1 - 12
[4] Rivastigmine: An acetylcholinesterase inhibitor for patients with Alzheimer's disease
White, CM
Dicks, RS
[J]. FORMULARY, 1999, 34 (06) : 493 - +
[5] Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
Sharma, JC
[J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (06) : 414 - 415
[6] Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease
Rösler, M
Retz, W
Retz-Junginger, P
Dennler, HJ
[J]. BEHAVIOURAL NEUROLOGY, 1998, 11 (04) : 211 - 216
[7] Bradyarhythmia during cholinesterase inhibitor therapy in patients with Alzheimer's disease
Osmonov, Damirbek
Ozcan, Kazim S.
Altay, Servet
Erdinler, Izzet
Turkkan, Ceyhan
Yildirim, Ersin
Gurkan, Kadir
[J]. CIRCULATION, 2012, 125 (19) : E850 - E851
[8] Drug persistency of two cholinesterase inhibitors - Rivastigmine versus donepezil in elderly patients with Alzheimer's disease
Suh, DC
Thomas, SK
Valiyeva, E
Arcona, S
Vo, L
[J]. DRUGS & AGING, 2005, 22 (08) : 695 - 707
[9] Mitochondrial Electron Transport Chain Protein Abnormalities Detected in Plasma Extracellular Vesicles in Alzheimer's Disease
Yao, Pamela J.
Eren, Erden
Goetzl, Edward J.
Kapogiannis, Dimitrios
[J]. BIOMEDICINES, 2021, 9 (11)
[10] Disease progression in Alzheimer's disease patients treated with a cholinesterase inhibitor in clinical practice
Gustavsson, A.
Parmler, J.
Ganguly, R.
Minthon, L.
Jonsson, L.
[J]. VALUE IN HEALTH, 2007, 10 (03) : A82 - A82

← 1 2 3 4 5 →